Esperion Therapeutis.Inc. buy Maxi_Scalibusa
Summary
This prediction ended on 22.05.18 with a price of €34.91. Massive losses of -49.25% were the result for the BUY prediction by Maxi_Scalibusa. Maxi_Scalibusa has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Esperion Therapeutis.Inc. | 2.389% | 2.389% | 51.421% | -89.221% |
iShares Core DAX® | 4.015% | 2.971% | 16.492% | 19.144% |
iShares Nasdaq 100 | 2.755% | 0.503% | 40.029% | 50.636% |
iShares Nikkei 225® | -0.826% | -5.057% | 14.566% | 2.379% |
iShares S&P 500 | 2.330% | 0.720% | 30.194% | 44.181% |
Comments by Maxi_Scalibusa for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Hot Stock